HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer

INTRODUCTION: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas from patients treated within the neoadjuvant...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Denkert, Carsten, Huober, Jens, Loibl, Sibylle, Prinzler, Judith, Kronenwett, Ralf, Darb-Esfahani, Silvia, Brase, Jan C, Solbach, Christine, Mehta, Keyur, Fasching, Peter A, Sinn, Bruno V, Engels, Knut, Reinisch, Mattea, Hansmann, Martin-Leo, Tesch, Hans, von Minckwitz, Gunter, Untch, Michael
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3672694/
https://ncbi.nlm.nih.gov/pubmed/23391338
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3384
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars